Sunesis Pharmaceuticals — JPMorgan Healthcare Conference 2019
30 slides from Sunesis Pharmaceuticals's conference presentation, Jan 7, 2019

Slide 1: JPMorgan Conference Update January 2019
JPMorgan Conference Update January 2019

Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation contains forward-looking statements, including statements related to the continued development of vecabrutinib (SNS-062) and other product candidates, including the timing and preliminary results of Phase 1b/2 trial of vecabrutinib and the therapeutic potentia

Slide 3: Sunesis Overview: Kinase Inhibitor Pipeline
Pre Clinical Phase 1 Phase 2 Phase 3 B-Cell Malignancies Vecabrutinib BTK Hematology/Solid Tumors SNS-510 PDK1 Sunesis Overview TAK-580 Pediatric Low-grade Glioma Key Milestones 2Q19: vecabrutinib clinical update at major medical conference 3Q19: vecabrutinib enters Phase 2 cohort expansion Kinase I

Slide 4: Strong Growth Continues for BTK-Inhibitor Market
Strong Growth Continues for BTK-Inhibitor Market Imbruvica: first covalent BTK inhibitor approved Imbruvica 2017sales: >$4B CLL market share leader (across all lines of therapy) EvaluatePharma estimates 2024 sales >$9B Company annual reports and earnings releases, EvaluatePharma World Preview Report

Slide 5: Relapse From Ibrutinib Associated with Acquired Resistance Mutations
Relapse From Ibrutinib Associated with Acquired Resistance Mutations Other Events 25%@ 4 years CLL Progression 19.1% @ 4 years Transformation 9.6% @ 4 years Woyach et al., J Clin Oncol 2017 Landmark Analysis of 308 Ibrutinib-Treated Patients 51% Discontinuation at 4 years Ibrutinib Acquired Resistan

Slide 6: Understanding Prevalence of BTK Mutations
Understanding Prevalence of BTK Mutations ERIC (European Research Initiative on CLL) international, retrospective, observational, multicenter study To determine the prevalence of BTK and PLCg2 mutations in CLL patients relapsing or responding to ibrutinib in a real-world setting Presented at EHA 201

Slide 7: Non-covalent BTK inhibitor
Vecabrutinib Non-covalent BTK inhibitor

Slide 8: BTK Kinase Domain Interaction Differentiated from Ibrutinib
Vecabrutinib BTK Kinase Domain Interaction Differentiated from Ibrutinib Cys481 vecabrutinib ibrutinib Hinge αC-helix Thr474 (gatekeeper) Activation loop Cys481 Hinge αC-helix Thr474 (gatekeeper) Activation loop Vecabrutinib distinct kinase domain interaction translates into improved selectivity ove

Slide 9: Selective Kinase Inhibitor
Vecabrutinib - Selective Kinase Inhibitor Inhibits BTK with nanomolar potency Highly selective: IC50 < 100 nM in only 4 of 234 non-Tec family kinases1 Lack of EGFR inhibition: 1000-fold less potent than ibrutinib Emerging ITK role in CLL and other indications: Improves T cell number and function2 Co

Slide 10: Differentiated Kinase Inhibition Profile
Vecabrutinib Differentiated Kinase Inhibition Profile TEC Family Kinases Inhibition of Other Kinases IC50 (nM) BTK ITK Tec# TXK* BMX* Notable Target Kinases Ibrutinib2 0.5 10.7 78 2.03 0.8 >10 more: EGFR family Acalabrutinib3 5.1 >1000 93 368 46 Selective Zanubrutinib4 0.22 30 1.9 n/a n/a N/A (not p

Slide 11: Active in Wild-type and C481S Mutant BTK
Vecabrutinib Active in Wild-type and C481S Mutant BTK Activity of ibrutinib and acalabrutinib is profoundly affected1-4 Poor PK contributes to resistance in patients with BTK C481 mutations Vecabrutinib active against BTK C481S mutation and induces apoptosis in BTK-dependent lymphoma cell lines1-4 C

Slide 12: Inhibition of ITK-Mediated Cellular Activities Comparable to Ibrutinib
Vecabrutinib Inhibition of ITK-Mediated Cellular Activities Comparable to Ibrutinib Inhibition of IL-2 Production Inhibition of PLCɣ1 Phosphorylation Sunesis data 1Tam et al., ASH 2015 VEC IC50 nM IBR IC50 nM ZAN1 IC50 nM 275 168 2536 VEC IC50 nM IBR IC50 nM ZAN1 IC50 nM 438 412 3433 IL-2 production

Slide 13: Superior PK Profile Critical for Non-covalent BTK Inhibitor Activity
Vecabrutinib Superior PK Profile Critical for Non-covalent BTK Inhibitor Activity 1 Neuman et al., ASH 2016 2 Adapted from Byrd et al., NEJM 2016 3 Adapted from Tam et al., ASH 2015 4 Adapted from Advani et al., J. Clin. Oncol. 2013 5 IMBRUVICA® (ibrutinib) prescribing information. Sunnyvale, CA: Ph

Slide 14: Phase 1a: Profound and Sustained Target Inhibition
Phase 1a: Profound and Sustained Target Inhibition Rapid, near complete inhibition of pBTK at all dose levels Prolonged inhibition seen at dose levels of ≥ 100 mg, supporting BID dosing Target dose level in patients likely 100-300 mg BID As concentrations increased, inhibition increased and variabil

Slide 15: Phase 1b/2 Trial Status and Preliminary Data in B-Cell Malignancies
Vecabrutinib in B-Cell Malignancies Phase 1b/2 Trial Status and Preliminary Data

Slide 16: Phase 1b/2 Study Design
Vecabrutinib in B-Cell Malignancies Phase 1b/2 Study Design Cohort 1 25 mg BID Cohort 2 50 mg BID Cohort 3 100 mg BID Cohort 4 200 mg BID RP2D Cohort Expansion Or continue escalation 300, 400, 500 mg BID CLL/SLL, MCL, WM, DLBCL-ABC, FL, MZL ≥ 2 prior regimens, includes BTK inhibitor if approved for

Slide 17: Phase 1b/2 Study Status
Vecabrutinib in B-Cell Malignancies Phase 1b/2 Study Status Currently open in United States at 8 sites: 13 subjects treated to date 25 mg BID cohort: N=3 50 mg BID cohort: N=10 7 completed safety evaluation Safety profile supported dose escalation Cohort 3 (100 mg BID) open 3 subjects assigned slots

Slide 18: Preliminary Data – ASH 2018 Baseline Characteristics
Vecabrutinib Preliminary Data – ASH 2018 Baseline Characteristics All Subjects N=11a CLL Subjects N=7b Indication 7 CLL, 2 MCL, 2 WM Unmutated IGHV 5 (71%) Median age (range) years 66 (47-75) TP53 mutations /deletions 6 (86%) ECOG PS 0 3 (27%) BTK C481 Mutationsc 4 (57%) ECOG PS 1 8 (83%) Prior ther

Slide 19: Preliminary Data – ASH 2018 Safety
Vecabrutinib Preliminary Data – ASH 2018 Safety N=10 Adverse Event All Grades >15% N(%)a Grade ³ 3 N Related, Grade ³ 3 N Adverse Event All Grades >15% N(%) a Grade ³ 3 N Related, Grade ³ 3 N Anaemia 7 (70) 6 1 Constipation 2 (20) Neutropenia 5 (50) 5 1 Cough 2 (20) Night sweats 5 (50) Diarrhea 2 (2

Slide 20: Vecabrutinib Steady-State Mean PK Profiles in B-Cell Malignancy Patients
C2D1 C1D8 Generally dose proportional Sustained vecabrutinib exposure over dosing interval Vecabrutinib Steady-State Mean PK Profiles in B-Cell Malignancy Patients Consistent with Healthy Subjects Allan et. al. (ASH 2018 – Poster # 3141); Sunesis internal data

Slide 21: Treatment Induced Rapid and Sustained Inhibition of BTK Phosphorylation
Vecabrutinib Treatment Induced Rapid and Sustained Inhibition of BTK Phosphorylation Inhibition of pBTK for 5 subjects (4 CLL , 1 MCL) whose baseline C1D1 predose samples had adequate signal Postdose samples taken at 1 or 4 hours after dosing Allan et. al. (ASH 2018 – Poster # 3141); Sunesis interna

Slide 22: Treatment Decreased Serum Cytokines in Subjects Who Completed Cycle 1
Vecabrutinib Treatment Decreased Serum Cytokines in Subjects Who Completed Cycle 1 Consistent with inhibition of BTK signaling Baseline levels higher than previously reported in CLL (may indicate advanced disease) Median (range) pg/mL: CCL2 545.7 (11.8-2561.9), CCL3 320 (68.6-567), CCL4 1039 (22.5-3

Slide 23: Summary: Preliminary Vecabrutinib Profile & Status
Summary: Preliminary Vecabrutinib Profile & Status Safety – appears well-tolerated in the context of advanced disease Pharmacokinetics – sustained exposure over dosing interval and generally dose proportional Pharmacodynamics – inhibition of BTK phosphorylation & cytokine reduction seen in patients

Slide 24: Proprietary Pipeline SNS-510, PDK-1 inhibitor
Proprietary Pipeline SNS-510, PDK-1 inhibitor

Slide 25: SNS-510 PDK1 Inhibitor: Exciting Preclinical Cancer Program
SNS-510 PDK1 Inhibitor: Exciting Preclinical Cancer Program Modality Small-molecule, oral inhibitor of PDK-1 Molecular Hypothesis Major mediator of PI3K signaling and activator of AKT PI3K-independent activator of RSK and S6K kinases Therapeutic Hypothesis Potentially broader activity than PI3K/AKT

Slide 26: PDK1 Is the Major Mediator of PI3K Signaling
PDK1 Is the Major Mediator of PI3K Signaling Master kinase that activates kinases important to cell growth and survival in the AKT, PKC, RSK and SGK families Cunningham J T , and Ruggero D Cancer Discovery 2013;3:1099-1102

Slide 27: Summary
Summary

Slide 28: Financial Position and Capitalization
Financial Position and Capitalization 1 As of 9/30/18 2 As of 10/31/18; includes common (37.4M) and preferred as converted (6.3M) 3 As of 10/31/18 Ticker SNSS (NASDAQ) Cash & Equivalents $20.2 million1 Debt $7.5 million1 Shares 43.8 million2 Warrants Stock Options 0.2 million @ avg $3.723 3.4 millio

Slide 29: Sunesis Highlights
Sunesis Highlights Large and rapidly growing market for BTK inhibitors Validated target, clear mechanism of action Covalent-BTK-inhibitor resistance is a growing problem Near-term milestones expected to create significant value Global rights retained for both BTK and PDK1 programs

Slide 30: Thank You
)) SUME SIS | Pharmaceuticals, In. Thank You
Source: SEC EDGAR · 8-K filed Jan 7, 2019
More decks from Sunesis Pharmaceuticals Inc
Viracta Therapeutics — Investor Presentation (October 2023)47 slides · Oct 4, 2023
Viracta Therapeutics — Corporate Update (August 2021)34 slides · Aug 12, 2021
Viracta Therapeutics — Investor Presentation (April 2021)24 slides · Apr 14, 2021
Merger or Acquisition (January 2021)23 slides · Jan 7, 2021
Merger or Acquisition (November 2020)11 slides · Nov 30, 2020
Investor Presentation (March 2020)33 slides · Mar 18, 2020